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Introductory Paragraph
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel virus that emerged in 
2012, causing acute respiratory distress syndrome (ARDS), severe pneumonia-like symptoms, and 
multi-organ failure, with a case fatality rate of ~36%. Limited clinical studies indicate that humans 
infected with MERS-CoV exhibited pathology consistent with late stages of ARDS, which is 
reminiscent of disease observed in patients infected with SARS coronavirus. Models of MERS-
CoV-induced severe respiratory disease have been difficult to achieve, and small animal models 
traditionally used to investigate viral pathogenesis (mouse, hamster, guinea pig, and ferret) are 
naturally resistant to MERS-CoV. Therefore, we used CRISPR/Cas9 to modify the mouse genome 
to encode two human amino acids (288 and 330) in the dipeptidyl peptidase 4 receptor, making 
mice susceptible to MERS-CoV replication. Serial MERS-CoV passage in these engineered mice 
was then used to generate a mouse-adapted virus that replicated efficiently within the lungs, and 
evoked symptoms indicative of severe acute respiratory distress syndrome (ARDS), including 
decreased survival, extreme weight loss, decreased pulmonary function, pulmonary hemorrhage, 
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and pathological signs indicative of end stage lung disease. Importantly, therapeutic 
countermeasures comprising MERS-CoV neutralizing antibody treatment or a MERS-CoV spike 
protein vaccine protected engineered mice against MERS-CoV-induced ARDS.
The severity of respiratory illness caused by MERS-CoV, its pandemic potential through 
human-to-human respiratory transmission, and a dearth of effective treatments necessitates 
the development of new MERS-CoV therapies and vaccines. Effective vaccine and 
therapeutic development requires preclinical animal models that resemble the pathogenesis 
of human MERS-CoV infection. Additionally, these models should: i) include a measure of 
mortality associated with severe respiratory disease; ii) not be confounded by neurological 
complications due to high viral loads in the brain; iii) exhibit sustained, high level viral 
replication within the lungs of infected animals; iv) exhibit lung pathology associated with 
human ARDS; v) maintain innate expression of the MERS-CoV host receptor, dipeptidyl 
peptidase 4 (DPP4) to prevent perturbation of immunological homeostasis; vi) be genetically 
tractable to study host genes that regulate responses to MERS-CoV vaccines and 
therapeutics; and vii) exhibit reproducibility.
Conventional non-human primate (NHP) models have been established for MERS-CoV in 
both the rhesus macaque and common marmoset1–4. NHPs are instrumental for the 
preclinical development of therapeutics, however, these models are cost prohibitive for 
initial screening of large numbers of vaccine and therapeutic candidates, challenging to work 
with for routine pathogenesis studies, limited in availability and typically require high viral 
challenge doses into multiple sites. Furthermore, two recent studies contradict the initial 
studies in NHPs, which may complicate use of either the rhesus macaque5 or the common 
marmoset6 models for routine vaccine or therapeutic testing.
MERS-CoV fails to replicate in traditional small animal models (mouse, hamster, guinea 
pig, and ferrets), due to the inability of the receptor binding domain (RBD) in the MERS-
CoV spike protein to interact with the respective DPP4 receptor7–10. In addition to acting as 
the MERS-CoV receptor, DPP4 regulates T cell activation, cytokine function, and trans-
endothelial migration to sites of inflammation11. Therefore, overexpression of DPP4 may 
result in immune dysregulation. Effective models would therefore, ideally promote 
functional MERS-CoV/DPP4 interactions, with minimal perturbations of innate DPP4 
expression, signaling activity, or tissue distribution. Classic strategies to overcome receptor 
incompatibilities to generate susceptible mice have relied on generalized or tissue-specific 
transgenic over-expression approaches to drive expression of the human receptor (hDPP4) in 
the mouse12–15. Although MERS-CoV can elicit respiratory disease in hDPP4 
overexpression models, these models exhibit a fatal CNS and systemic multi-organ 
disease12–14, likely due to non-specific overexpression of receptor throughout the animal, 
which complicates the study of MERS-CoV-induced respiratory pathogenesis in these 
models.
In this manuscript, we leveraged our knowledge of which determinants allow mouse DPP4 
to act as a functional MERS-CoV receptor7 by using CRISPR/Cas9 genome editing 
technology to insert human codons at positions 288 and 330 in the mouse DPP4 gene. This 
strategy resulted in a mouse that is permissive for MERS-CoV infection, while maximally 
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preserving the species-specific interaction networks critical for DPP4 immune function. 
Generation of mice carrying a chimeric mDPP4 molecule (A288L/T330R), combined with a 
mouse adapted strain of MERS-CoV, allowed us to generate a mouse model that resembles 
severe MERS-CoV-induced respiratory disease without bystander neurologic disease. In 
parallel, we demonstrate that this model system can be used for the development and testing 
of MERS-CoV vaccines and therapeutics.
Results
A CRISPR/Cas9 generated mouse model for MERS-CoV infection
We had previously demonstrated that the introduction of two human amino acids at positions 
288 and 330 in the mouse DPP4 (mDPP4) receptor can support MERS-CoV docking, entry, 
and replication in cell culture7. These determinants are located at exons 10 and 11 of 
mDPP4 on chromosome 2 (Fig. 1a and Supplemental Fig. 1). Therefore, we used CRISPR/
Cas9 genome editing to concomitantly introduce these determinants (A288L and T330R) 
into the mouse DPP4 receptor (Fig. 1a and Supplemental Table 1). Two lines of C57Bl/6J-
derived mice were generated that were either homozygous (288-330+/+) or heterozygous 
(288-330+/−) for the chimeric mDPP4 alleles (Fig. 1a). The 288-330+/+ homozygous mice 
encode the 288L and 330R changes on both chromosomes, thereby only expressing mDPP4 
with both changes (Fig. 1a). The 288-330+/− heterozygous mice encode the 288L and 330R 
changes on one chromosome and the C57Bl/6J wild-type amino acids, A288 and T330, on 
the other chromosome, thereby expressing both mutated and wild-type mDPP4 (Fig. 1a). 
The innate mDPP4 expression levels and patterns in the lungs, kidneys, and brains of 
288-330+/+ and 288-330+/− mice reflect those observed in C57Bl/6J wild-type mice (Fig. 1b 
and 1c; Supplemental Fig. 2). Dipeptidyl peptidase 4 is central to the maintenance of 
glucose homeostasis in mammals16. Blood glucose levels are within the normal range 
observed in C57Bl/6J wild-type mice, supporting the hypothesis that biological mDPP4 
functions were not altered in 288-330+/+ and 288-330+/− mice (Supplemental Fig. 2). 
Moreover, basal CD4+ T cell expression of IL-2, TNF-α, IFN-γ, CD69, CD25 and mDPP4 
(CD26) from the 288-330+/+ and 288-330+/− lines was comparable to the levels observed in 
C57Bl/6J wild-type mice (Supplemental Fig. 3). Notwithstanding functional T cell 
assessment, these results suggest that minimal alteration of the 288 and 330 alleles does not 
alter basal T cell activation status. Overall expression levels, expression patterns, biological 
function, and immunological profiles of mDPP4 are comparable to those of C57Bl/6J wild-
type mice following site-specific modification of the 288 and 330 alleles.
The 288-330+/+ and 288-330+/− mice support efficient infection and replication of the human 
MERS-CoV strain HCoV-EMC/2012, the camel MERS strain Dromedary/Al-Hasa-KFU-
HKU13/2013, and a recombinant virus derived from a molecular infectious clone (icMERS), 
in the lungs, but these virus strains could not replicate in C57Bl/6J wild-type mice that retain 
the original murine A288 and T330 alleles (Fig. 1d). In parallel, a MERS-CoV tissue-culture 
adapted variant derived by infection of NIH3T3 cells ectopically expressing the chimeric 
mDPP4 (A288L/T330R) receptor, was found to encode a 3 amino acid insertion and a single 
amino acid change (RMRL) in the S2 region of the spike gene. MERS-0, a recombinantly 
derived virus encoding the RMRL S2 mutations, demonstrated significantly enhanced 
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replication both in cell culture (Supplemental Fig. 4) and in the lungs of 288-330+/+ and 
288-330+/− mice (Fig. 1d). Despite replicating to significantly higher virus titers in vivo than 
the other isolates, MERS-0 exhibited no evidence of severe clinical disease symptoms 
(Supplemental Fig. 4). Lung histology demonstrated that nucleocapsid antigen from 
MERS-0, and the other strains, was readily detected in the lungs of infected mice by 
immunohistochemistry, but infected lungs exhibited only moderate signs of respiratory 
pathology and inflammation (Fig. 1e). These results demonstrated that we developed a 
MERS-CoV model that can support high levels of viral replication through day 3 post-
infection, but required further in vivo adaptation to achieve respiratory symptoms 
characteristic of MERS-CoV infection in humans.
Mouse adaptation of MERS-CoV induces ARDS-like severe respiratory disease
The recombinantly-derived MERS-0 virus was then mouse adapted by serial passage for 15 
rounds through the lungs in 288-330+/− mice at 3 day intervals, resulting in the MERS-15 
strain. Infection of 288-330+/+ mice via the intranasal (IN) route with MERS-15 resulted 
in ~70% mortality (genuine mortality, rather than mice meeting the typical 20% weight loss 
cutoffs associated with human euthanasia criteria), while 100% of infected 288-330+/− mice 
survived (Fig. 2a). Nonetheless, both lines exhibited 20–25% weight loss by day 6 post-
infection, in contrast to MERS-0 infected 288-330+/+ mice or MERS-15 infected C57Bl/6J 
wt mice which exhibited no weight loss (Fig. 2b). Significantly higher levels of MERS-15 
replication was detectable in the lungs of both 288-330+/+ and 288-330 +/− mice at days 3 
and 6 post-infection, while MERS-0 was mostly cleared from the lungs by day 6 post-
infection (Fig. 2c and 2d). Similar to MER-0, MERS-15 could did not replicate in wild type 
C57Bl/6 mice. Importantly, the observed decreases in survival and weight loss induced by 
MERS-15 were not confounded by neurological complications from brain infection, as 
plaque assays for replication competent virus and RT-PCR at days 3 and 6 post-infection 
were negative (Supplemental Fig. 5). Moreover, qRT-PCR on the same samples 
demonstrated >106 increase in detectable viral transcripts in infected lungs compared to 
similarly infected C57Bl/6J mice, with no detectable viral transcripts in the brains of these 
mice.
Although mortality and weight loss provide important measures of MERS-CoV-induced 
disease, these parameters do not directly assess the impact of viral replication on respiratory 
function. Therefore, to directly assess the impact of MERS-15 infection on respiratory 
function in 288-330+/+ or 288-330+/− mice, we measured respiratory function using 
unrestrained plethysmography, as previously demonstrated for respiratory pathogenesis in 
mouse models of SARS and influenza17. MERS-15 elicited severe lung disease as quantified 
by Penh (enhanced pause), a unit-less measure that reflects airway obstruction/restriction 
due to debris in the airway, and EF50 (mid-tidal expiratory flow), which represents the flow 
rate at which 50% of the tidal volume has been expelled, in a single breath17. MERS-15 
infection led to significant increases in both Penh and EF50 in 288-330+/+ and 288-330+/− 
mice through day 6 post-infection, compared to 288-330+/+ mice infected with MERS-0 and 
C57Bl/6J wt mice infected with MERS-15 (Fig. 3a & 3b), demonstrating that MERS-15 
elicits severe respiratory distress in mice carrying the chimeric DPP4 receptor. This was 
further supported by our observation of severe hemorrhage in lungs from both 288-330+/+ 
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and 288-330+/− mice infected with MERS-15 at days 3 and 6 (Supplemental Fig. 6), 
inflammatory infiltrates by day 3 (Fig. 3c), and respiratory pathology associated with severe 
acute respiratory distress, including hyaline membrane formation, intraalveolar edema, 
perivascular cuffing, and severe inflammation, at day 6 post-infection (Fig. 3d). Quantitative 
comparison of the lung pathology in 288-330+/+ mice infected with MERS-15 and MERS-0 
demonstrates that MERS-15 induces significant levels of pathology commensurate with 
ARDS by day 6 post-infection (Supplemental Fig. 7). Although we have not conducted an 
exhaustive assessment of every extra-pulmonary tissues in the 288-330+/+ mice, we could 
not detect viral replication in the brain even at doses of 5×106 PFU through day 6 when the 
humane euthanasia endpoints were reached, and the pathology observed in our model is 
consistent with severe respiratory pathology associated with fatal ARDS in the only 
published case study of a human MERS-CoV infection18.
Identification of MERS-CoV adapted mutations associated with severe respiratory disease
We anticipated that the MERS-CoV genome would acquire mutations due to immunological 
pressure, and/or enhanced virus fitness, during mouse adaptation. Two viral clones, 
MERS-15 clone 1 (MERS-15 C1) and MERS-15 clone 2 (MERS-15 C2) were isolated by 
plaque purification from the MERS-15 heterogeneous virus population. MERS-15 C2 
showed increased mortality (Fig. 4a) and significantly increased hemorrhage through day 6 
post-infection (Supplemental Fig. 8), whereas both clonal isolates showed 25–30% weight 
loss (Fig. 4b) and high levels of virus replication through day 6 post-infection when humane 
euthanasia endpoints were reached (Fig. 4c). The lung pathology elicited by MERS-15 C2 
resembled that obtained with the primary MERS-15 virus (Fig. 4d), demonstrating similar 
pathologies including edema, hyaline membrane formation, and perivascular cuffing. 
Sequencing of the entire MERS-15 C2 genome revealed a set of unique missense mutations, 
acquired during in vivo passaging, in nsP2, nsP6, and nsP8, and a large deletion in Orf4b 
that may be responsible for the enhanced disease observed with MERS-15 (Supplemental 
Fig. 9). Sequencing of MERS-15 C1 revealed some differences that may influence the 
capacity of the virus to elicit the increased mortality observed with MERS-15 C2, namely 
mutations in nsP2 and an expanded deletion that extends from Orf4b into Orf5 
(Supplemental Fig. 9). Moreover, 5′-RACE revealed that the nucleotide at position 2 of the 
5′ UTR is deleted in both clones (Supplemental Fig. 9). Generation of an infectious clone 
harboring all of the MERS-15 C2 mutations (icMERSma1) demonstrated that disease could 
be recapitulated with an infectious dose of 5×106 PFU (Supplemental Fig. 10). Decreasing 
the dose by 10-fold to 5×105 PFU resulted in weight loss that paralleled what is observed 
with 5×106 PFU, however the 5×105 PFU dose exhibited a slight decrease in mortality 
through day 7 post-infection (Supplemental Fig. 10). Although additional studies will be 
needed, comparative genomic analysis of clones 1 and 2 indicates that nsP2 and Orf5 may 
have a significant role in determining disease outcome. Therefore, the MERS-15 C2 derived 
virus, combined with the 288-330+/+ mouse line, represent useful tools for studying MERS-
CoV pathogenesis or assessing therapeutic countermeasures against MERS-CoV-induced 
ARDS.
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3B11, human monoclonal antibody, protects from MERS-CoV elicited severe respiratory 
disease
Human monoclonal antibodies (hmAB) provide a robust strategy for the treatment of newly 
emerged viruses in humans. HmAB 3B11 is a human antibody that targets the RBD of the 
MERS-CoV spike protein19, which is effective in non-human primates5. Since the MERS-15 
C2 adapted virus acquired no RBD mutations (Supplemental Fig. 9), we reasoned that 3B11 
hmAb should protect 288-330+/+ mice from MER-15 C2 challenge. As hypothesized, pre-
treating mice for 12 hours with 3B11 provided 100% protection against MERS-15 C2 
challenge (Fig. 5a & 5b). Moreover, 3B11 treatment reduced viral loads in the lungs of 
infected mice to undetectable levels (Fig. 5c and Supplemental Fig. 11), and protected from 
loss of respiratory function (Fig. 5d) (Supplemental Fig. 11), pulmonary hemorrhage 
(Supplemental Fig. 11) and severe pathological changes (Supplemental Fig. 12). In contrast, 
pretreatment with isotype control antibody provided no protective effect. Therefore, these 
data convincingly demonstrate that our preclinical mouse model of severe respiratory 
disease and mortality, can serve as a platform for assessing MERS-CoV therapeutics.
VRP-derived spike protein vaccines protect from lethal infection
To examine vaccine efficacy in the 288-330+/+/MERS-15 C2 model, mice were vaccinated 
with Venezuelan equine encephalitis replicon particles (VRPs) expressing MERS-CoV spike 
protein (spike-VRP), or mock vaccinated with VRPs that express GFP (GFP-VRP), boosted 
at 4 weeks post prime, and challenged with MERS-15 C2 at 4 weeks post-boost. All mice 
receiving spike-VRP survived and exhibited no weight loss following challenge, compared 
to GFP-VRP mock vaccinated animals (Fig. 6a and 6b). Spike-VRP vaccination 
significantly reduced MERS-15 C2 replication in the lungs of infected mice by both plaque 
titer (Fig. 6c) and by viral antigen staining (Supplemental Fig. 14), while also protecting 
from severe respiratory disease as assessed by Penh (Fig. 6d) and EF50 (Supplemental Fig. 
13), lung hemorrhage (Supplemental Fig. 13), and pathological indications of severe acute 
respiratory disease (Supplemental Fig. 14). Neutralization of MERS-15 C2 with pre-
challenge serum from spike-VRP vaccinated mice validated the presence of high titer 
neutralizing antibodies in the serum of vaccinated 288-330+/+ mice (Supplemental Fig. 13). 
Our data demonstrate that the spike-VRP vaccine provokes an adaptive immune response 
capable of protecting mice from a lethal challenge of MERS-CoV, thereby extending the 
utility of our preclinical mouse model of severe respiratory disease to include vaccine 
evaluation.
Discussion
The MERS-CoV preclinical mouse model described here demonstrates for the first time that 
the CRISPR-Cas9 system can be employed to genetically edit a non-permissive host 
receptor to generate a susceptible model for an emerging infectious pathogen. The 
288-330+/+ MERS-CoV mouse model resembles the severe, and often fatal, respiratory 
distress syndrome observed in humans that can be prevented through treatment with the 
3B11 neutralizing monoclonal antibody19, or a VRP-based vaccine directed to the MERS-
CoV spike protein15,20. Coupled with an inability to elicit escape mutants, 3B11 has also 
been tested in NHPs5, making it an excellent candidate for downstream human studies. 
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However, existing NHP models rely on qRT-PCR, rather than measures of infectious virus, 
to quantify viral loads, and these models do not reproducibly result in the severe respiratory 
disease or mortality observed in human MERS patients1–4. Therefore, the results from our 
model complements the NHP 3B11 studies by directly demonstrating that 3B11 does reduce 
levels of infectious MERS-CoV in the lungs, while preventing severe virus-induced 
respiratory pathology, loss of respiratory function, and mortality.
In fatal cases of human MERS-CoV infections, individuals exhibit severe respiratory distress 
requiring mechanical ventilation, and the only published human autopsy from a MERS-CoV 
fatality reported histopathology that included diffuse alveolar damage with denuding of 
bronchiolar epithelium, hyaline membrane formation, type 2 pneumocyte hyperplasia, and 
edema18. Furthermore, MERS-CoV antigen staining localized the virus to pneumocytes and 
syncytial cells18. Infection of type I and II pneumocytes can lead to cell death as observed in 
autopsies of patients that have died from severe respiratory infections with influenza and 
SARS21,22. Moreover, pneumocyte cell death has been proposed to cause decreased 
respiratory function as measured by whole body plethysmography in a mouse model of 
influenza23. Commensurate with these previous studies our MERS-CoV mouse model 
demonstrates wide-spread infection of pneumocytes and pathology consistent with diffuse 
alveolar damage and severe respiratory disease. This is corroborated with decreased 
pulmonary function in the MERS-CoV model, as measured by plethysmography, which may 
be associated with widespread infection, and possibly death of pneumocytes and airway 
epithelial cells. Therefore, this model system provides the field with the opportunity to 
investigate the mechanisms that lead to MERS-CoV-induced pathology and severe 
respiratory disease, in the absence of any CNS complications.
Other MERS-CoV mouse models have employed the more traditional method of expressing 
the full-length human DPP4 receptor to facilitate MERS-CoV infection12–15,24. These 
models exhibited infection/replication in the lungs following intranasal administration at low 
viral doses (102–105 PFU), which in some cases resulted in pathology indicative of 
pneumonia-like disease12–14. One limitation of 288-330+/+ MERS-CoV model described 
here is the use of high viral loads to achieve severe, and often, fatal respiratory disease. 
Further adaptation may afford the use of lower infectious doses that would allow for a model 
of mild disease with subsequent recovery at later time points, as has been described with 
SARS-CoV25. In this context, it is interesting that the deletion of MERS-CoV ORF4b, a 
phosphodiesterase and antagonist of RNAseL activity in human cells, appeared less critical 
for eliciting severe disease in rodents26, suggesting possible species specific modes of action 
in vivo. Deletions in some SARS-CoV interferon antagonist genes and accessory ORFs have 
also yielded subtle changes in overall virulence in vivo as well27,28. However, it is also 
important to point out that balance must be achieved between the virulence of mouse 
adapted virus, which enhances the model’s capacity to replicate human disease phenotypes, 
and the number of mutations required to significantly reduce the LD50 dose.
Conventional models employing constitutive overexpression of hDPP4 MERS-CoV receptor 
demonstrate widespread infection of extra-pulmonary tissues including brain, kidney, liver, 
spleen and heart12–14, and two of these studies indicated that the mice exhibit multi-organ 
failure13,14. Furthermore, high viral loads were detected in the brains of mice in all 
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transgenic hDPP4 overexpression models12–14. Importantly, Li et al. concluded that 
“mortality correlated with brain infection, suggesting that infection of this organ was most 
important for the high mortality observed in K18-hDPP4 mice”13. While these lethal models 
have value for vaccine and immunotherapeutic testing29, small molecule inhibitors that are 
effective in the lung may be limited in their efficacy due to an inability to cross the blood 
brain barrier30. Similar neurologic complications were observed in model systems for SARS 
that used over-expression, or tissue-specific constitutive promoters, to express human 
angiotensin 1 converting enzyme 2 (ACE2) in mice31. While additional human pathology 
studies are needed to determine the extent of extra-pulmonary sites of MERS-CoV 
replication and their impact on MERS-CoV disease, it is clear that respiratory replication 
and pathology is an important aspect of human MERS-CoV disease. Therefore, an important 
attribute of the 288-330+/+ model is that the lack of detectable viral replication in the CNS 
means that this model can be used to study MERS-CoV-induced pulmonary disease without 
the confounding effects of death due to CNS infection.
Recently, a debate has emerged around the safety of performing GOF studies with highly 
pathogenic viruses (MERS-CoV, SARS-CoV, Influeza H5N1, etc.) (http://
www.gryphonscientific.com/gain-of-function/). As demonstrated here, GOF studies were 
absolutely necessary to develop a mouse model that reflects ARDS pathology previously 
observed in humans infected with respiratory pathogens. Importantly, the GOF studies 
performed here yielded MERS-CoV strains that reflect the complexity of clinical isolates 
recently identified in humans, wherein deletions were identified in Orf3 and Orf4a32. 
Moreover, these GOF studies have allowed us to identify mutations in MERS-CoV proteins 
that may influence how MERS-CoV interacts with, and possibly circumvents, host immune 
responses. Nevertheless, future studies to evaluate host factors that contribute to MERS-CoV 
disease will be constrained in this model, as well as hDPP4 expression models, by the fact 
that the mice must be back-crossed to mouse lines harboring modified endogenous genes 
(e.g. knock-out mice). This limitation may be overcome through additional GOF studies that 
facilitate MERS-CoV adaptation to the innate mouse DPP4 receptor molecule. The 
continued threats from novel emerging pathogens (e.g. Zika virus) will command the rapid 
development of physiologically relevant animal models to evaluate therapeutic 
countermeasures, thereby necessitating viral adaptation to host immunity to achieve effective 
models. It is critical that the GOF regulatory structure not impede the development of robust 
animal models of human disease, which are essential for protecting the public health.
Methods
Viruses, cells, and plaque assays
All virus stocks were prepared on Vero CCL81 cells (ATCC, Manassas, VA). Vero CCL81 
cells were routinely maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Sigma, F2442) and 1X 
antibiotic/antimycotic (Gibco, Carlsbad, CA). All viruses were harvested in OptiMEM 
media (Gibco, Carlsbad, CA) supplemented with 3% FBS, 1X antibiotic/antimycotic, 1X 
nonessential amino acids (Gibco, Carlsbad, CA), and 1X sodium pyruvate (Gibco, Carlsbad, 
CA). The wild-type EMC2012 strain of MERS-CoV was used at passage 10 (originally 
Cockrell et al. Page 8
Nat Microbiol. Author manuscript; available in PMC 2017 August 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
provided by Bart Haagmans at passage 8), infectious clone MERS (icMERS) was previously 
generated by the Baric lab33, MERS camel strain Dromedary/Al-Hasa-KFU-HKU13/2013 
was used at passage 5 and was provided at passage 4 by Malik Peiris (University of Hong 
Kong, China), and MERS-0 was generated by the Baric lab as described below. Virus titers 
were determined by plaque assays on Vero CCL81 cells33. All viruses were maintained 
under biosafety level (BSL)3 conditions with redundant fans and personnel powered-air 
purifying respirators (PAPRs), scrubs, Tyvek suits, Tyvek aprons, and double layers of 
gloves.
An icMERS-tRFP virus33 was passaged for 10 rounds on NIH3T3 cells (ATCC, Manassas, 
VA) that were generated to stably overexpress the mDPP4 receptor containing A288L and 
T330R, referred to here as 288/330 mDPP4 NIH3T3 cells. The mDPP4 A288L/T330R 
expression cassette used to generate the cell line was described previously7. Sequencing of 
the passaged virus identified a 3 amino acid (RMR) insertion after amino acid 884 in the 
spike protein and an S885L change. These changes were sub-cloned back into the MERS-
CoV infectious clone by overlap PCR of the F fragment with the following primers: 5′-
ggTTTCCAgAAgTgTgAgCAATTACTgCgCg-3′, 5′-
gCAggCCTCTgCAgTCgACgggCCCgggATCCAATgCC-3′, 5′-
CCTgTTTCTATATCTACTggCAgTCgTAgAATgCggCTTgCACgTAgTgCTATTgAggATTT
gC-3′, and 5′-
gCAAATCCTCAATAgCACTACgTgCAAgCCgCATTCTACgACTgCCAgTAgATATAgAA
ACAgg-3′. The F fragment is one part of a 7 plasmid system (A, B, C, D1, D2, E, and F) 
that permits partitioning of the entire genome to generate infectious MERS-CoV viruses, as 
described previously33. The PCR product encoding the insertion was sub-cloned back into 
the F fragment with MscI and BamHI restriction enzymes, and validated by sequencing. 
Recombinant MERS-0 virus was used for the in vivo passage experiments, which were gain-
of-function (GOF) studies reviewed and approved by the National Institutes of Health 
(NIH). Vero-81 and NIH-3T3 cells were originally received from ATCC, which indicates 
that cell lines are authentic and confirms that cell lines are mycoplasma free. None of the 
working cell line stocks were authenticated or tested for mycoplasma recently, although the 
original seed stocks used to create the working stocks are free from contamination. 
Additionally, both cell lines are authenticated by morphological and cytopathological 
evaluation. Furthermore, Vero-81 cells are confirmed for DPP4 overexpression by capacity 
to be infected, and replicate MERS-CoV.
Generation of mice with mouse DPP4 modified at position 288 (exon 10) and 330 (exon 11)
The alleles encoding amino acids 288 and 330 are shown in Supplemental Figure 1. 
Genomic engineering of these alleles with the CRISPR/Cas9 genome editing system was 
performed at the UNC-CH Animal Models Core Facility. The mRNA encoding Cas9 
endonuclease and guide RNAs (gRNAs) were based on the system established by Mali et 
al.34 and prepared as described here. Guide RNAs (Supplemental Table 1) were generated 
through in vitro transcription reaction using T7 High Yield RNA Synthesis Kit (NEB 
#E2040S), wherein 1 μg DraI linearized template DNA was used in a 20 μl reaction 
following kit guidelines for short RNA transcripts. The reaction was incubated at 37°C 
overnight, followed by DNase I (RNase-free) digestion for 15 mins at 37°C. The gRNAs 
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were then purified using an RNeasy Column following guidelines for short RNA purification 
(Qiagen). Capped and polyadenylated Cas9 mRNA was prepared through in vitro 
transcription reaction using mMESSAGE mMACHINE T7 ULTRA KIT (Life Technologies, 
AM1345). Capped mRNA was generated with 1 μg hCas9-T7 linearized plasmid DNA 
added into a 20 μl reaction containing 1X NTP/ARCA, 1X T7 reaction buffer, and 2 μl T7 
enzyme. The reaction was incubated at 37°C for 1 hour, followed by addition of 1 μl 
TURBO DNase and digestion at 37°C for 15 mins. To add a PolyA tail to the capped 
mRNA, the 20 μl reaction mix from step 1 was mixed with nuclease-free water (36 μl), 5X 
E-PAP Buffer (20 μl), 25 mM MnCl2 (10 μl), ATP Solution (10 μl), and E-PAP (4 μl) to a 
final reaction volume of 100 μl. The reaction was incubated at 37°C for 30–45 mins. The 
capped & polyadenylated RNA was purified by LiCl precipitation and resuspended in 
microinjection buffer (5 mM Tris, 0.1 mM EDTA, pH 7.5).
Fertilized zygotes were collected from C57BL/6J females that had been super ovulated and 
mated to C57BL/6J males. Pronuclear microinjection was performed with 50 ng/μl Cas9 
mRNA, 50 ng/μl guide RNA Dpp4-g59B, 25 ng/μl guide RNA Dpp4-g88B and 50 ng/μl 
each Dpp4-A288L-B and Dpp4-T330R-B donor oligos (Supplemental Table 1). Injected 
embryos were implanted into pseudopregnant recipients and resulting pups were screened 
for alleles encoding changes (Supplemental Fig. 1) at positions 288 and 330. Mutations at 
the 288 position were detected by amplifying biopsy DNA samples with the following 
primers: Dpp4-E10ScF1 5′-GATTCTGAGCAAGCAAACACGC-3′and Dpp4-E10ScR1 5′-
CCACAAGGTATCCCACAGAGACG-3′. The 752 bp PCR product was sequenced with 
primer Dpp4-E10-SqR1 5′-CAAGAACCACACCAATGGAAAGTC-3′. Mutations at the 
330 position were detected by amplifying biopsy DNA samples with the following primers: 
Dpp4-E11ScF1 5′-AAGTGCTGGGATTATAGGTGGTCAC-3′ and Dpp4-E11ScR1 5′-
GTGTTTACATTCTAAGTTGGGTTTCTGC-3′. The 767 bp PCR product was sequenced 
with primer Dpp4-E11-SqF1 5′-GCATGTTATCCACTGTGCCATCTC-3′. Five of 66 live 
animals produced showed evidence of both the 288 and 330 modifications. Founders with 
both expected modifications were backcrossed to C57Bl/6J mice to identify animals with the 
288 and 330 modifications in cis. F1 animals with both the 288 and 330 modifications were 
then intercrossed to produce homozygous breeder pairs for colony enrichment and 
downstream studies.
Mouse infections
Genetically engineered mice, with modified mouse DPP4 receptor, were housed and bred in 
accordance with guidelines established by the Department of Laboratory Animal Medicine 
(DLAM) at The University of North Carolina at Chapel Hill (UNC-CH). Since the 
288-330+/+ and 288-330+/− mice are novel mouse lines developed in the Baric lab, 
experiments utilized available male and female mice that ranged 12–20 weeks of age. Based 
on availability at the time of each experiment, experimental and control animals were age- 
and sex-matched. No blinding was used in any animal experiments, and animals were not 
randomized. Sample sizes were determined from preliminary data that would yield 
statistically significant differences. Mouse studies were executed under ABSL3 conditions 
as described previously35. Prior to viral infection mice were anesthetized by administering 
50μl of a ketamine/xylazine mixture intraperitoneally, and then infected intranasally with a 
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50μl volume of virus at 5 × 106 PFU. Incomplete infections due to bubbling of inoculum 
from the nasal cavity, inability to inhale the entire dose, or inoculum going into the mouth 
were noted, and these mice were considered failures and were excluded, as done 
previously35. Following sedation and infection mice were monitored daily for weight loss 
and survival, as well as signs that animals were moribund (including labored breathing, lack 
of movement, and lack of grooming). Mice that reached 20% weight loss were placed under 
exception, and monitored at least twice daily. Mice that approached 30% weight loss were 
immediately euthanized. Mice deemed moribund were euthanized at the discretion of the 
researcher. Mice were euthanized with an isoflurane overdose followed by a secondary 
thoracotomy, at the time point indicated in results, for collecting lung tissues. In the absence 
of a thoracotomy, cervical dislocation was used as a secondary euthanasia method. All are 
approved methods of the Institutional Animal Care and Use Committee (IACUC) at The 
University of North Carolina at Chapel Hill.
Ethics Statement
Mouse studies were executed in accordance with the recommendations for the care and use 
of animals by the Office of Laboratory Animal Welfare (OLAW) at NIH. The Institutional 
Animal Care and Use Committee (IACUC) at UNC-CH approved the animal studies 
performed here (protocol, IACUC 13–272), using a ~30% weight loss for humane 
euthanasia. Synthetically reconstructed MERS-CoV viruses were approved by the UNC-CH 
Institutional Biosafety Committee (IBC), which also considered gain-of-function research 
concerns prior to execution of these experiments.
Analysis of Serum Glucose Levels
All blood glucose measurements were taken following a six hour fast. Blood glucose was 
measured via tail clip sampling using an AlphaTRAK 2 glucometer (Abbott Laboratories)36. 
This system is designed for use in laboratory mice with a normal range of 111 to 205 mg/dL 
(6.1 to 11.38 mmol/L) blood glucose, and a detection limit of 20 to 750 mg/dL (1.1 to 41.62 
mmol/L).
Adaptation of MERS-0 in humanized mice
The recombinant virus MERS-0 was passed through the lungs of 288-330+/− mice every 
three days for 15 passages to obtain a MERS-CoV (MERS-15), adapted to cause respiratory 
disease in mice. At each passage the lungs were homogenized and 50μl of lung homogenate 
was used for intranasal infection of a naïve 288-330+/− mouse. The MERS-15 mouse-
adapted virus was assessed for survival, weight loss, lung titer, hemorrhaging, respiratory 
function, and histopathology indicative of diffuse alveolar damage and acute respiratory 
distress syndrome. Clonal isolates of the MERS-15 virus were obtained by plaque 
purification, amplification on Vero CCL81 cells, and sequenced to determine mutations 
acquired during mouse adaptation of the virus. All sequencing was performed at the UNC-
CH Genome Analysis Facility. MERS-15 clone 2 recapitulated the severe respiratory disease 
observed with MERS-15, therefore all subsequent experiments were performed with the 
plaque-purified MERS-15 clone 2.
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Human monoclonal 3B11 antibody protection study
The 288-330+/+ mice were prophylactically administered 250μg of either 3B11 human 
monoclonal antibody or F10 isotype control antibody by intraperitoneal injection19 12 hours 
prior to infection with MERS-15 clone 2. Mice were monitored daily for weight and 
survival, and sacrificed at days 3 and 6 post-infection to collect lungs for histology, viral titer 
by plaque assay, and evaluation of lung hemorrhaging. Respiratory function was measured at 
day 0 to establish a baseline and then again at days 3 and 6 post-infection. The isolation and 
production of the 3B11 and F10 antibodies was as previously described19.
Spike-VRP vaccine study and Virus Neutralization Assay
The MERS-CoV gene encoding the spike protein and GFP gene were packaged into 
Venezuelan equine encephalitis virus (VEE) replicon particles generated with helper 
constructs from the 3526 attenuated strain, under BSL2 conditions, as previously 
demonstrated20. Mice were administered a prime vaccination of 10μl by footpad injection of 
either spike-VRP (1×105 PFU) or the control GFP-VRP (1×105 PFU). Twenty-eight days 
later mice were boosted with the same dose of their respective VRP strain. At 28 days post-
boost, all vaccinated mice were challenged with 5×106 PFU of MERS-15 clone 2. Mice 
were monitored daily for weight and survival, and sacrificed at days 3 and 6 post-infection 
to collect lungs for histology, viral titer by plaque assay, and evaluation of lung 
hemorrhaging. Respiratory function was measured at day 0 to establish a baseline and then 
again at days 3 and 6 post-infection.
The presence of MERS-15 clone 2 specific serum antibodies was assessed by the plaque 
reduction neutralization titer assay. Pre-challenge serum samples were collected at 25 days 
post-boost with the Spike-VRP vaccine and the GFP-VRP mock. Virus neutralization assays 
were performed as described previously35. The percentage of plaque reduction was 
calculated as (1- (no. of plaques with Spike-VRP or GFP-VRP serum/no. of plaques with 
serum from naïve 288-330+/+ mice)) × 100.
Respiratory Function
Respiratory function was measured for individual mice, at the indicated time points, as 
demonstrated previously for SARS-CoV and Influenza A virus17. Briefly, individual mice 
were acclimated for 30 minutes in individual plethysmography chambers (Buxco Systems, 
Wilmington, NC), and then each breath was quantitated over a 5 minute period. Mice were 
routinely randomized into different chambers to avoid measurement biases that could result 
between chambers. Data for enhanced pause (Penh) and expiratory flow rate at 50% tidal 
volume (EF50) were analyzed as previously described by our group17.
Histology
Lung, brain, and kidney samples were placed in 10% phosphate buffered formalin for 
>7days at 4°C for fixation. Fixed tissue samples were then removed from the BSL3 placed 
into cassettes for embedding in paraffin, and submitted to the Lineberger Comprehensive 
Cancer Center Animal Histopathology Core for processing, sectioning and staining. Tissue 
sections (5μm) were stained for hematoxylin and eosin, and for MERS-CoV nucleocapsid 
antigen using mouse anti-MERS nucleocapsid serum at 1:250 dilution. The nucleocapsid 
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antiserum was generated in the Baric lab using MERS-CoV nucleocapsid-VRP particles in 
Balb/c mice as described previously20. Antigen was visualized using DAB staining. An 
Olympus DP71 camera attached to an Olympus BX41 microscope was used to capture 
images with 10X and 40X objectives. Histopathology was scored, blinded to infection and 
and animal status, for airway disease, vascular disease, parenchymal pneumonia, diffuse 
alveolar damage, eosinophils, and immunohistochemistry on a scale of 0 to 3 where 0 = 
none, 1 = mild, 2 = moderate, and 3 = severe.
Flow Cytometry Analysis
Whole peripheral blood from each mouse strain was collected in EDTA and mononuclear 
cells (PBMCs) were purified using density gradient centrifugation over Ficoll-Paque PLUS 
(GE Healthcare Life Sciences, Piscataway, NJ). Mouse lung tissues were first mechanically 
dissociated using scalpel blades then further digested using type A collagenase (Worthington 
Biochemical, Lakewood, NJ) in media prepared with DNase I (1mg/ml) for 1 hour in a 
shaking incubator at 37°C. Digested lung suspensions were filtered, centrifuged and treated 
with ACK lysis buffer. Single cell suspensions from blood and lung tissue were resuspended 
at 1×107 cells/ml in RPMI 1640 media supplemented with 10% heat-inactivated FBS and 
antibiotic/antimycotic cocktail (all Gibco), and were used immediately for flow cytometry. 
Single cell suspensions were plated in 200μl volumes per well on 96-well, round-bottom 
plates and stained for flow cytometry using the Intracellular Fixation and Permeabilization 
Buffer Set (eBioscience, San Diego, CA) according to the manufacturer’s protocol and 
antibodies specific for CD3 (clone 145-2C11), CD4 (clone GK1.5), CD8 (clone 53-6.7; 
eBioscience), CD25 (clone PC61), CD26/DPP4 (clone H194-112; Biolegend, San Diego, 
CA), CD69 (clone H1.2F3; eBioscience), IFN-γ (clone XMG1.2), TNF-α (clone MP6-
XT22; eBioscience), and IL-2 (clone JES6-5H4; eBioscience). All antibodies were 
purchased from BD Bioscience (San Jose, CA), unless indicated. Cells were also treated 
with a Fixable Live/Dead Discriminator (Invitrogen). Stained cells were fixed for 20 minutes 
in 1% PFA, resuspended in PBS and stored at 4°C before acquisition within 24 hours. Cell 
populations were first gated to exclude i) debris, ii) doublet events, and iii) dead cells before 
phenotypic and functional gating. All samples were stained in parallel with fluorescence 
minus one controls. A minimum of 100,000 live, singlet events were acquired per sample 
and data were analyzed using FlowJo software (TreeStar, Ashland, OR).
Northern Blot Analysis and RT-PCR
Northern blot analysis was performed for detection of full-length mouse DPP4 in the lungs 
of 288-330+/+, 288-330+/−, and C57Bl/6J wild-type mice. Poly (A) RNA was isolated to 
eliminate ribosomal RNA (Qiagen). Equivalent amounts of RNA were resolved on 0.8% 
agarose gels and transferred to nitrocellulose membrane. A biotinylated probe, 5′-
[Btn]gATg[BtndT]gCTggTgAgCTgTgCTgCTAgCgATCCCgTggTCTTCATCC-3′, was 
used to detect mouse DPP4.
For quantifying viral and targeted host mRNAs, MERS-CoV, mouse DPP4, and mouse 
GAPDH RNAs were measured in brain and lung tissue from MERS-CoV-infected mice. 
Briefly, tissues were removed and placed into RNALater (Ambion) solution and stored at 
−80°C until analysis by RT-PCR. Lung tissue was homogenized in TRIzol reagent 
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(Invitrogen), and isolated according to manufacturer’s instructions. Standard RT-PCR was 
performed with the following primer pairs for each of the indicated RNAs: MERS-CoV 
subgenomic transcript MERS leader 5′-CTATCTCACTTCCCCTCgTTCTC-3′ and 59R 5′-
GAATCATTGTTAGGGTTCCG-3′; mGAPDH 5′-CAACgACCCCTTCATTgACC-3′ and 
mGAPDH 5′-gCAgggATgATgTTCTgggC-3′; and, mouse DPP4 5′-
TAACgACACAggAgTgCCgC-3′ and mouse DPP4 5′-TCTgCTTTTTgACTACAggg-3′. 
Equivalent volumes of PCR product were resolved on the gels for a non-quantitative answer 
(presence or absence) of viral subgenomic transcript in the brain and lung.
Quantitative RT-PCR was executed on a Roche LightCycler 480 II, with accompanying 
software, to analyze MERS-CoV viral RNA, mDPP4 mRNAs, and 18S ribosomal RNA as 
an endogenous control. All RNAs were reverse transcribed under standard conditions in a 
20μl reaction volume using SuperScript III reverse transcriptase (Invitrogen). MERS-CoV 
viral RNA was assessed using 900nM of the following primers in a 20μl reaction with SyBr 
Green assay with 2X SsoAdvanced Universal SYBR Green Supermix (Biorad). The forward 
primer anneals at the MERS-CoV leader sequence in the 5′ UTR (5′-
GAATAGCTTGGCTATCTCAC-3′) and reverse primer anneals in the N gene (5′-
TTGTTATCGGCAAAGGAAAC-3′). PCR conditions were 45 cycles of 95°C/10sec, 59°C/
10sec, and 72°C/15sec. Standard Taqman conditions were used to analyze expression of 
mDPP4 and 18S ribosomal RNAs. The following primers and probe were used for mDPP4: 
Forward primer (5′-CCCCAAGACAGTGTGGATTC-3′); reverse primer (5′-
GAGGATGAGCTGAGAGAGTCTATATTT-3′); and probe #51 was used from the Roche 
Universal ProbeLibrary. PCR conditions were 45 cycles of 95°C/15sec and 60°C/50sec. A 
20X commercially available primer-probe set was utilized to quantitate the 18S ribosomal 
RNA (Life Technologies).
Statistical analysis
All quantitative data are presented as averages ± one standard deviation (SD). Significance 
between specific data sets is described in the respective figure legend and was determined 
using the student t-test function using a one-tailed or two-tailed distribution in Microsoft 
Excel software.
Biosafety and biosecurity
In vivo adaptation of the MERS-0 virus in mice had been executed prior to the US 
Government Deliberative Process Research Funding Pause on Selected Gain-of-Function 
Research Involving Influenza, MERS and SARS viruses http://www.phe.gov/s3/dualuse/
Documents/gain-of-function.pdf). When notice to cease all in vivo passage experiments was 
received, all studies to adapt the MERS-0 virus in vivo where immediately halted. Following 
our formal written request for continuation, and then receiving an exemption from the pause 
and approval to continue after NIAID/NIH review, the in vivo adaptation of MERS-0 was 
then continued by serial passage in mice. All studies comprising the use of MERS-CoV 
where executed in BSL3 facilities at UNC-CH, under conditions described previously35.
The following biosafety and biosecurity paragraph is as described by Menachery et al.35. All 
work for these studies was performed with approved standard operating procedures (SOPs) 
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and safety conditions for MERS-CoV (not a select agent), SARS-CoV (select agent), and 
derivatives therein. Our institutional CoV BSL3 facilities have been designed to conform to 
the safety requirements that are recommended in the Biosafety in Microbiological and 
Biomedical Laboratories (BMBL), the US Department of Health and Human Services, the 
Public Health Service, the Centers for Disease Control (CDC) and the NIH. Laboratory 
safety plans were submitted to, and the facility has been approved for use by, the UNC 
Department of Environmental Health and Safety (EHS) and the CDC. Electronic card access 
is required for entry into the facility. All workers have been trained by EHS to safely use 
powered air purifying respirators (PAPRs), and appropriate work habits in a BSL3 facility 
and active medical surveillance plans are in place. Our BSL3 facilities contain redundant 
fans, emergency power to fans and biological safety cabinets and freezers, and our facilities 
can accommodate SealSafe mouse racks. Materials classified as BSL3 agents consist of 
MERS-CoV, SARS-CoV, bat CoV precursor strains, and mutants derived from these 
pathogens. Within the BSL3 facilities, experimentation with infectious virus is performed in 
a certified Class II Biosafety Cabinet (BSC). All members of the staff wear scrubs, Tyvek 
suits and aprons, PAPRs and shoe covers, and their hands are double-gloved. BSL3 users are 
subject to a medical surveillance plan monitored by the University Employee Occupational 
Health Clinic (UEOHC), which includes a yearly physical, annual influenza vaccination and 
mandatory reporting of any symptoms associated with CoV infection during periods when 
working in the BSL3. All BSL3 users are trained in exposure management and reporting 
protocols, are prepared to self-quarantine and have been trained for safe delivery to a local 
infectious disease management department in an emergency situation. All potential exposure 
events are reported and investigated by EHS and UEOHC, with reports filed to both the 
CDC and the NIH.
Data Availability
The data that support the findings of this study are available from the corresponding author 
upon request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A CRISPR/Cas9 genetically engineered mouse model for MERS-CoV replication. (a) 
CRISPR/Cas9 genetically engineered C57Bl/6J mice to encode 288L & 330R on mDPP4 of 
one chromosome (heterozygous, 288-330+/−) and 288L & 330R on both chromosomes 
(homozygous, 288-330+/+). (b) Northern blot of mDPP4 mRNA expression. (c) 
Immunohistochemistry (IHC) of mDPP4 protein in the lungs, brain, and kidneys of 
individual C57Bl/6J wild-type, 288-330+/−, and 288-330+/+ mice. (d) Viral titers for MERS-
CoV at 3 days p.i. from C57Bl/6J wild-type (n = 4), 288-330+/− (n = 4), and 288-330+/+ (n = 
4) mice infected with the indicated viruses at 5×105 PFU. Bar graphs are averages +SD. 
Student t-test was used to calculate p < 0.05 for comparisons of MERS-0 with each virus in 
288-330+/+ mice (a, b, c) and 288-330+/− mice (d, e, f). (e) Pathology of 288-330+/+, 
288-330+/−, and C57Bl/6J wild-type mice at 3 days p.i. with MERS-0. Lung tissue sections 
were stained to examine pathology by H&E, or stained by IHC to detect nucleocapsid 
protein from MERS-0 infection. IHC and H&E pathology images are representative of at 
least 3 samples. Scale bars in lower right panels are 1mm.
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Figure 2. 
Mouse adapted MERS-CoV causes fatal disease in 288-330+/+ mice. Mice were inoculated 
intranasally with 5×106 PFU. (a) Mortality of 288-330+/− (n = 10) and 288-330+/+ (n = 16) 
mice was monitored daily through day 6 post-infection. Data reflect percent of surviving 
mice. (b) Mouse weights were measured daily through day 6 post-infection for 288-330+/+ + 
MERS-15 (n = 16); 288-330+/− + MERS-15 (n = 10), 288-330+/+ + MERS-0 (n = 10), and 
C57Bl/6J wt + MERS-15 (n = 7). Data are daily averages of the percent weight relative to 
day 0 ±SD. (c) Viral lung titers for MERS-CoV were determined at day 3 (n = 4 for 
288-330+/− + MERS-15; n = 5 for 288-330+/+ + MERS-15; n = 5 for 288-330+/+ + MERS-0; 
n = 4 for C57Bl/6J wt + MERS-15) and day 6 (n = 4 for 288-330+/− + MERS-15; n = 4 for 
288-330+/+ + MERS-15; n = 5 for 288-330+/+ + MERS-0; n = 3 for C57Bl/6J wt + 
MERS-15) post-infection. The limit of detection (LOD) is indicated. Bars are averages +SD. 
(d) Immunohistochemistry of lung sections for anti-MERS nucleocapsid at 3 days post-
infection. 288-330+/+ + MERS-15 (i); 288-330+/− + MERS-15 (ii); 288-330+/+ + MERS-0 
(iii); and C57Bl/6J wt + MERS-15 (iv). IHC images are representative of at least 3 samples. 
Scale bars in lower right panels are 1mm.
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Figure 3. 
Lung function in MERS-15-infected mice. Respiratory function was monitored in live mice 
through day 6 p.i. using whole-body plethysmography to measure enhanced pause (Penh) (a) 
and the expiratory flow rate at 50% tidal volume (EF50) (b) in 288-330+/+ + MERS-15 (n = 
9); 288-330+/− + MERS-15 (n = 4), 288-330+/+ + MERS-0 (n = 3), and C57Bl/6J wt + 
MERS-15 (n = 3). Data are daily averages ±SD. Student t-test was used to compare 
288-330+/+ mice infected with MERS-15 and MERS-0, # is p < 0.01 and * is p < 0.05. (c) 
Pathology of lungs from infected mice at day 3 p.i. demonstrate severe inflammation for 
288-330+/+ (i) and 288-330+/− (ii) infected with MERS-15, and moderate inflammation for 
288-330+/+ + MERS-0 (iii) and C57Bl/6J wt + MERS-15 (iv). (d) Pathology at day 6 post-
infection for 288-330+/+ + MERS-15 images demonstrate severe inflammation and edema in 
large airways and alveoli (i) and (ii), and hyaline membrane formation (iii). 288-330+/− + 
MERS-15 exhibit severe inflammation throughout parenchyma (iv), hyaline membrane 
formation (v), and perivascular cuffing (vi). 288-330+/+ + MERS-0 (vii) or C57Bl/6Jwt + 
MERS-15 (viii) exhibit mild-to-moderate inflammation. All images are at 40X 
magnification. H&E images are representative of at least 3 samples. Scale bars in lower right 
panels are 1mm.
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Figure 4. 
Clonal isolates of mouse-adapted MERS-CoV exhibit severe respiratory disease. Mice were 
inoculated intranasally with 5×106 PFU. (a) Mortality of 288-330+/+ + MERS-15 clone 1 
(MERS-15 C1) (n = 7) or MERS-15 clone 2 (MERS-15 C2) (n = 11) was monitored daily 
through day 6 p.i. Data reflect percent of surviving mice. (b) Mouse weights were monitored 
daily for 288-330+/+ + MERS-15 C1 (n = 7); 288-330+/+ + MERS-15 C2 (n = 11); 
288-330+/+ + MERS-0 (n = 6); and C57Bl/6J wt + MERS-15 C2 (n = 6). Data are daily 
averages ±SD. (c) Viral lung titers were determined at day 3 (288-330+/+ + MERS-15 C1, n 
= 4; 288-330+/+ + MERS-15 C2, n = 3; 288-330+/+ + MERS-0, n = 3; and C57Bl/6J wt + 
MERS-15 C2, n = 3) and day 6 (288-330+/+ + MERS-15 C1, n = 4; 288-330+/+ + MERS-15 
C2, n = 6; 288-330+/+ + MERS-0, n = 3; and C57Bl/6J wt + MERS-15 C2, n = 3). The limit 
of detection (LOD) is indicated. Bar graphs are averages +SD. (d) IHC of lung sections at 3 
days p.i. from 288-330+/+ + MERS-15 C1 (i) or MERS-15 C2 (ii) stained for nucleopcapsid. 
Pathology of lungs from 288-330+/+ + MERS-15 C2 was assessed by H&E at day 6 p.i. 
Images demonstrate severe inflammation (iii), edema (iv), hyaline membrane formation (v), 
and perivascular cuffing (vi). Images are at 40X magnification. All H&E images are 
representative of at least 3 samples. Scale bar in lower right panel is 1mm.
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Figure 5. 
Human monoclonal antibody, 3B11, protects mice from severe respiratory disease. 
288-330+/+ mice were intraperitoneally administered 250ug of 3B11 or isotype control 
antibody 12 hours prior to challenge with 5×106 PFU of MERS-15 C2. Mortality (a) and 
mouse weights (b) were monitored daily for mice receiving 3B11 human monoclonal 
antibody (n = 12) or isotype control antibody (n = 12) through day 6 p.i. Data reflect percent 
surviving mice (a) or daily weight averages ±SD (b). (c) Viral lung titers were determined at 
day 3 (n = 6 for each of 3B11 and isotype control antibody treated mice) and day 6 (n = 6 
for 3B11 treated mice; n = 3 for isotype control antibody treated mice). The limit of 
detection (LOD) is indicated. Bar graphs are averages +SD. (d) Lung function was assessed 
by Penh (enhanced pause) at 0, 3, and 6 days p.i. for mice receiving 3B11 (n = 6 at days 0, 3, 
and 6) or isotype control (n = 6 at days 0 and 3, and n = 3 at day 6). Data are averages +SD. 
Student t-test was used to compare mice receiving 3B11 human monoclonal antibody with 
the isotype control antibody at day 3 (# is p < 0.01) and day 6 (* is p < 0.01) p.i.
Cockrell et al. Page 22
Nat Microbiol. Author manuscript; available in PMC 2017 August 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
Vaccination of 288-330+/+ mice with a VRP delivering MERS-CoV spike protein protects 
mice from challenge with MERS-CoV. The vaccination protocol is described in methods. 
After a 5×106 PFU challenge, mortality (a) and mouse weights (b) were monitored daily for 
mice receiving GFP-VRP (n = 19) or Spike-VRP (n = 19) through day 6 p.i. Data reflect 
percent survival (a) or daily weight averages ±SD (b). (c) Viral lung titers were determined 
day 3 (n = 7 for Spike-VRP and GFP-VRP) and day 6 (n = 12 for Spike-VRP; n = 6 for 
GFP-VRP) p.i. The limit of detection (LOD) is indicated. Bar graphs are averages +SD. (d) 
Lung function was assessed by Penh (enhanced pause) at 0, 3, and 6 days p.i. for mice 
receiving either GFP-VRP (n = 12 at days 0 and 3 p.i.; n = 6 at day 6 p.i.) or Spike-VRP (n = 
12 at all days post-infection). Data represent averages +SD. Student t-test was used to 
compare mice receiving GFP-VRP with Spike-VRP vaccines at day 3 (# is p < 0.01) and day 
6 (* is p < 0.01) p.i.
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